Skip to main content

Table 4 Adverse events in objective blood tests during the treatment and sequelae at the 10th week in patients between group I and group II

From: Triple therapy combined with ventriculoperitoneal shunts can improve neurological function and shorten hospitalization time in non-HIV cryptococcal meningitis patients with increased intracranial pressure

  Group I (AmB+ Group II (AmB+ P-value
Fluconazole + 5-FC) Fluconazole + 5-FC + VPS)
Adverse events (n, %) (n = 27) (n = 39)  
 Hypokalemia 13 (48.1%) 20 (51.3%) 0.804
 Transaminase elevation 14 (51.9%) 15 (38.5%) 0.285
 Renal impairment 5 (18.5%) 12 (30.8%) 0.267
 Hematological impairment 5 (18.5%) 14 (35.9%) 0.128
Sequelae (n = 27) (na = 36)  
 Headache 9 (33.3%) 9 (25.0%) 0.395
 Dizziness/vertigo 2 (7.4%) 5 (13.9%) 0.465
 Hemiparesis 4 (14.8%) 5 (13.9%) 0.850
 Visual 8 (29.6%) 6 (16.7%) 0.184
 Auditory 1 (3.7%) 7 (19.4%) 0.077
 Seizure 3 (11.1%) 2 (5.6%) 0.387
  1. a One patient was lost to -follow-up and two patients were death at the 10th week in Group II